Minodronic Acid

Summary

Minodronic Acid (CHEMBL319144) is an approved small molecule targeting GGPS1 and FDPS; indicated across 2 conditions including osteoporosis and postmenopausal osteoporosis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Targets: 2 (GGPS1, FDPS)
• Indications: 2 conditions
• Clinical trials: 7
• Chemistry: 322.15 Da · C9H12N2O7P2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL319144
Name	Minodronic Acid
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	130956
Molecular formula	C9H12N2O7P2
Molecular weight	322.15
InChIKey	VMMKGHQPQIEGSQ-UHFFFAOYSA-N

SMILES: C1=CC2=NC=C(N2C=C1)CC(O)(P(=O)(O)O)P(=O)(O)O

IUPAC name: (1-hydroxy-2-imidazo[1,2-a]pyridin-3-yl-1-phosphonoethyl)phosphonic acid

Also known as: Acide minodronique, Acido minodronico, Minodronate, Minodronic acid, NSC-725590, ONO-5920, YM 529, YM-529, YM529, SID144206806, minodronic acid, MINODRONIC ACID

Parent form; salt/anhydrous children: CHEMBL6195779

Patent coverage: 958 distinct patent families (2,895 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
GGPS1	geranylgeranyl diphosphate synthase	Inhibition	4	96.7% (common-essential)	O95749
FDPS	farnesyl diphosphate synthase	Inhibition	8.52	72.4%	P14324

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Farnesyl diphosphate synthase, Geranylgeranyl pyrophosphate synthase BTS1, Farnesyl pyrophosphate synthase, Geranylgeranyl pyrophosphate synthase.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
FDPS	8.72	IC50	1.9	nM	CHEMBL_ACT_15191323
FDPS	8.52	IC50	3	nM	CHEMBL_ACT_18897263
FDPS	8.52	IC50	3	nM	CHEMBL_ACT_3289107
Q12051	6.89	Ki	130	nM	CHEMBL_ACT_2129542
Q12051	6.47	IC50	340	nM	CHEMBL_ACT_2129535
GGPS1	6.17	IC50	670	nM	CHEMBL_ACT_3289109
P22939	5.96	IC50	1100	nM	CHEMBL_ACT_1804652
GGPS1	5.75	Ki	1800	nM	CHEMBL_ACT_2129556

Target pathways

Aggregated over 2 target gene(s): GGPS1, FDPS.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Cholesterol biosynthesis	2	FDPS, GGPS1
Activation of gene expression by SREBF (SREBP)	2	FDPS, GGPS1
Lanosterol biosynthesis	2	FDPS, GGPS1

Dominant GO biological processes

GO term	Targets
isoprenoid biosynthetic process	2
geranyl diphosphate biosynthetic process	2
trans, trans-farnesyl diphosphate biosynthetic process	2
lipid metabolic process	2
isoprenoid metabolic process	1
geranylgeranyl diphosphate biosynthetic process	1
cholesterol biosynthetic process	1
steroid biosynthetic process	1
steroid metabolic process	1
cholesterol metabolic process	1
sterol biosynthetic process	1

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
osteoporosis	3	MONDO:0005298	EFO:0003882
postmenopausal osteoporosis	1	MONDO:0008159	EFO:0003854

Clinical trials

Total trials: 7.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1	2
PHASE4	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05645289	PHASE4	UNKNOWN	Efficacy and Safety of Minodronate in Patients With Low Back Pain
NCT00212667	PHASE3	COMPLETED	Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
NCT00212719	PHASE3	COMPLETED	Controlled Study of ONO-5920 in Patients With Involutional Osteoporosis in Japan
NCT00794443	PHASE2/PHASE3	COMPLETED	ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients
NCT05305183	PHASE3	UNKNOWN	A Phase III Clinical Study of Minodronate Tablets in Postmenopausal Women With Osteoporosis
NCT00965978	PHASE1	COMPLETED	A Study to Evaluate Food Effect on ONO-5920/YM529 Intermittent Formulation
NCT02295436	PHASE1	COMPLETED	Pharmacokinetics and Tolerability of Minodronic Acid and Food and Age Effects on the Pharmacokinetics

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

12 molecules share ≥1 primary target. Top 12 by shared-target count:

Molecule	Source	Status	Shared targets
Alendronic Acid	ChEMBL + PubChem	Phase 4 (approved)	FDPS, GGPS1
IBANDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS, GGPS1
Pamidronic Acid	ChEMBL + PubChem	Phase 4 (approved)	FDPS, GGPS1
risedronic acid	ChEMBL + PubChem	Phase 4 (approved)	FDPS, GGPS1
ZOLEDRONIC ACID	ChEMBL + PubChem	Phase 4 (approved)	FDPS, GGPS1
Lovastatin	PubChem	Approved	FDPS, GGPS1
ALENDRONATE	ChEMBL	Phase 4 (approved)	FDPS
NERIDRONIC ACID	ChEMBL	Phase 3	FDPS
PYROPHOSPHORIC ACID	ChEMBL + PubChem	Phase 2 (approved)	FDPS
INCADRONIC ACID	ChEMBL	Phase 2	FDPS
PIRIDRONIC ACID	ChEMBL	Phase 2	FDPS
SQ109	ChEMBL	Phase 2	GGPS1